PUBLISHER: The Business Research Company | PRODUCT CODE: 1942697
PUBLISHER: The Business Research Company | PRODUCT CODE: 1942697
Depyrogenated sterile empty vials are borosilicate glass containers equipped with butyl-rubber stoppers and aluminum seals, designed for the storage of injectable drugs. Depyrogenation is a process that involves the removal of pyrogenic substances, including bacterial endotoxins, through the application of heat.
The main product types of depyrogenated sterile empty vials include 2 ml, 5 ml, 10 ml, 20 ml, and those exceeding 20 ml in volume. For example, a 2 ml vial refers to a container with a volume of 2 milliliters, commonly used for injectable drug storage. These vials are available in standard and large opening variations, typically used with aluminum seals. Depyrogenated sterile empty vials come in glass and plastic packaging, serving the needs of clinical labs, compounding labs, pharmaceutical companies, contract manufacturing organizations, and distributors.
Tariffs are impacting the depyrogenated sterile empty vials market by increasing costs of imported borosilicate glass, rubber stoppers, aluminum seals, and specialized sterilization equipment used in vial production. Pharmaceutical manufacturing hubs in North America and Europe are most affected due to dependence on imported raw materials, while Asia-Pacific faces pricing pressure on export-oriented vial manufacturing. These tariffs are increasing packaging costs and affecting supply contracts. However, they are also encouraging local glass manufacturing, regional supplier diversification, and investment in domestic sterile packaging infrastructure.
The depyrogenated sterile empty vials market research report is one of a series of new reports from The Business Research Company that provides depyrogenated sterile empty vials market statistics, including depyrogenated sterile empty vials industry global market size, regional shares, competitors with a depyrogenated sterile empty vials market share, detailed depyrogenated sterile empty vials market segments, market trends and opportunities, and any further data you may need to thrive in the depyrogenated sterile empty vials industry. This depyrogenated sterile empty vials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The depyrogenated sterile empty vials market size has grown strongly in recent years. It will grow from $3.79 billion in 2025 to $4.09 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to rising injectable drug production volumes, expansion of sterile pharmaceutical manufacturing, increasing regulatory scrutiny on injectable safety, growth of biologics and vaccines, adoption of borosilicate glass packaging.
The depyrogenated sterile empty vials market size is expected to see strong growth in the next few years. It will grow to $5.55 billion in 2030 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to increasing demand for biologics and biosimilars, rising investments in aseptic fill-finish facilities, expansion of contract manufacturing services, growing focus on contamination control, increasing adoption of pre-sterilized packaging. Major trends in the forecast period include increasing adoption of high-purity injectable packaging, rising demand for ready-to-fill vials, growing focus on endotoxin-free packaging standards, expansion of automated depyrogenation processes, enhanced emphasis on regulatory-compliant primary packaging.
The rising prevalence of infectious diseases worldwide is expected to drive the growth of the depyrogenated sterile empty vials market. Infectious diseases are conditions caused by harmful microorganisms such as bacteria, viruses, parasites, and fungi. Depyrogenated sterile vials are used for storing injectable medications involved in the treatment of these infectious diseases. Furthermore, depyrogenated sterile empty vials are also utilized for collecting laboratory samples. For example, in February 2024, the Health Security Agency, a UK-based government agency, reported a 10.7% increase in tuberculosis (TB) cases in England in 2023 compared to 2022. The number of cases grew from 4,380 in 2022 to 4,850 in 2023. As a result, the increasing prevalence of infectious diseases globally is expected to boost the growth of the depyrogenated sterile empty vials market.
Major companies operating in the depyrogenated sterile empty vials space are increasingly concentrating on the development of advanced solutions, such as deep-cold freeze vials, to address the rising need for safer and more dependable storage and transportation of biopharmaceutical products. Deep-cold freeze vials are specialized sterile containers engineered to securely store biological materials at extremely low temperatures, typically ranging from -80 °C to -150 °C. These vials help safeguard sensitive drugs, vaccines, and biological samples from degradation, preserve sterility, and maintain product integrity during long-term storage and distribution. For example, in January 2024, SCHOTT Pharma AG & Co. KGaA, a Germany-based specialty glass manufacturer, introduced EVERIC freeze vials, a novel vial family specifically designed for messenger ribonucleic acid and gene-therapy products that require deep-cold storage and robust container performance. The EVERIC freeze vials are Type I borosilicate glass containers that are manufactured and qualified for ultralow-temperature use; they incorporate reinforced glass geometry and tightly controlled production processes to minimize breakage during freeze-thaw cycles, are compatible with standard lyophilization and cryogenic logistics, provide precise dimensional control for automated filling and capping lines, and are designed to lower delamination and particulate risks while enhancing drug stability compared with conventional vials, making them well suited for vaccines, gene-therapy vectors, and other highly temperature-sensitive biologics.
In June 2023, ALK-Abello, Inc., a pharmaceutical company based in Denmark known for manufacturing sterile empty vials, entered into a strategic partnership with Galenova Inc., a Canada-based pharmaceutical company. Through this collaboration, ALK-Abello, Inc. aims to enhance its distribution network by providing dependable and high-quality glass vials to pharmacies and hospitals throughout Canada. Galenova Inc. specializes in pharmaceutical products, including the provision of depyrogenated sterile empty vials. This partnership reflects a joint effort to strengthen the supply chain and deliver essential pharmaceutical components to the Canadian healthcare system.
Major companies operating in the depyrogenated sterile empty vials market are APG Pharma, Corning Inc., DWK Life Sciences, Nipro PharmaPackaging, Schott AG, Thermo Fisher Scientific, Gerresheimer AG, Stevanato Group, SGD Pharma, Merck KGaA, SiO2 Materials Science, Shandong Pharmaceutical Glass Co. Ltd., West Pharmaceutical Services Inc., Ompi Srl, Pacific Vial Manufacturing Inc., Adelphi Healthcare Packaging Limited, Acme Vial and Glass Company LLC, Amposan S.A., BMT Corporation, Cangzhou Four Stars Glass Co. Ltd., Zhejiang Pharmaceutical-Packaging Co. Ltd.
North America was the largest region in the depyrogenated sterile empty vials market in 2025. The regions covered in the depyrogenated sterile empty vials market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the depyrogenated sterile empty vials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The depyrogenated sterile empty vials market consists of sales of type I borosilicate glass, and molded and tabular glass depyrogenated sterile empty vials. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Depyrogenated Sterile Empty Vials Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses depyrogenated sterile empty vials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for depyrogenated sterile empty vials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The depyrogenated sterile empty vials market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.